FDA Approves Eylea HD for Macular Edema

Here’s a breakdown of​ teh⁢ key⁣ data from ‍the provided text, focusing on the FDA approval of⁣ Eylea ‍HD and ⁣expert perspective:

Key⁤ Takeaways:

* ‌ FDA Approval: The FDA has​ approved Eylea HD for every-4-week (monthly) dosing across‍ all of its approved indications, including retinal vein occlusion ‌(RVO).Previously, the focus was on ‌less frequent dosing ⁢(every 8 weeks).
* ‌ Reduced Injection frequency: Eylea ‍HD possibly allows ⁢for ⁤a ‌halving⁣ of the number of injections‍ patients need compared to⁢ existing therapies for RVO. ⁤The text specifically mentions patients with RVO may benefit after 3-5 initial monthly doses.
* Flexibility ‍for Physicians: The approval ⁢gives doctors more options to⁢ tailor​ treatment to individual patient needs.
* Data supporting Approval: The approval is based ⁤on data from the ELARA (neovascular AMD) and QUASAR (RVO with macular ⁤edema) trials.
* Expert Opinion (David A.Eichenbaum, MD, FASRS):

*​ ⁤ The ⁢approval is a “tremendous change” for Eylea HD.
​ * While⁢ Eylea HD is effective at drying the⁣ macula,‍ some patients still need ⁢more frequent ⁢dosing to achieve and maintain dry anatomy.
​ ⁤ * Monthly dosing unlocks flexibility​ to use the‍ drug on more challenging cases of exudative macular disease.
​ * He is⁤ optimistic about the real-world performance ‌of Eylea HD with ‌more frequent dosing.
* Financial Disclosure: Dr.Eichenbaum⁣ has financial ties to both Bayer and​ Regeneron (consultant,​ investigator, and speaker).
* source: the information ⁢is published by Ocular Surgery News (via Healio).

In essence, this article reports ‌on a significant⁣ expansion of the approved uses for Eylea HD, making‌ it⁣ a more versatile treatment option for ​a wider range of patients with retinal diseases, especially ⁣those who require more ​frequent injections.